Home > > Europe And Global Direct to Consumer Genetic Testing Market- Size, Share, Growth Rate, and Forecast
The Europe Direct to Consumer Genetic Testing market was valued at $71,456.0 Million in 2023, and is projected to reach $83,166.4 Million by 2030 growing at a CAGR of 2.24% from 2024 to 2030. Clinical Chemistry segment is expected to be the highest contributor to this market, with $32,035.1 Million in 2023, and is anticipated to reach $37,231.9 by 2030, registering a CAGR of 2.22%. Medical Microbiology & Cytology segment is anticipated to reach $16,756.5 Million by 2030 with the highest CAGR of 2.39%. Clinical Chemistry and Human & Tumor Genetics segments collectively expected to account for about 69.0% share of the Europe Direct to Consumer Genetic Testing market in 2023, with the former constituting around 44.8% share. Medical Microbiology & Cytology and Human & Tumor Genetics segments are expected to witness significant growth rates at a CAGR of 2.39% and 2.34% respectively, during the forecast period. Presently, share of these two segments is estimated to be around 44.1% in the overall Europe Direct to Consumer Genetic Testing market in 2023, and is anticipated to reach 44.5% by 2030. Test Type Human & Tumor Genetics Clinical Chemistry Medical Microbiology & Cytology Other Test Types Service provider Hospital-based Laboratories Stand-alone Laboratories Clinic-based Laboratories BY REGION North America U.s. Canada Mexico Europe Germany France U.k. Italy Spain Russia Rest of Europe Asia China India Japan Australia Rest of Asia Middle East & Africa Brazil South Africa GCC Rest of MENA